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Purpose of the study
The aim of this meta-analysis study was to evaluate the
risk of death or AIDS defining event associated to CD4+
guided treatment interruption in patients with chronic
HIV infection.
Methods
A search was conducted using PubMed from 1/1/2000 to
31/12/2007. Heterogeneity was assessed through the
Cochran Q test and measured through the I2 index pro-
posed by Higgins & Thompson. Pooled relative risk e
pooled risk difference was calculated by use of random
effects model following DerSimonian & Laird methods.
Data were analysed using Stata statistical software version
9.0.
Summary of results
555 full papers were found, all abstracts were screened
and 58 full text articles for potential inclusion were
retrieved and seven were retained. The seven studies
included 3,409 patients that interrupted the therapy, and
3,173 patients that continued antiretroviral therapy.
Meta-analysis of the studies with a follow up >100 p/y
showed that the pooled relative risk of AIDS defining
event or mortality was 2.59 (95% CI 1.87–3.34; p <
0.001) (Q statistic for heterogeneity = 1.31, DF = 2, p =
0.52 I2 = 0); the pooled risk difference of AIDS defining
event or mortality was 0.02 (95% CI -0.01–0.05; p =
0.168) (Q statistic for heterogeneity = 35.11, DF = 3, p <
0.001, I2 = 91.5%, 95%CI 81.3–96.1%). The pooled rela-
tive risk of AIDS defining event or mortality corrected for
latest CD4+ value was 1.77 (95% CI 1.29–2.42; p < 0.001)
(Q statistic for heterogeneity = 0.82, DF = 2, p = 0.66, I2 =
0), the pooled risk difference of AIDS defining event or
mortality corrected for latest CD4+ value was 0.01 (95%
CI -0.01–0.02; p = 0.37) (Q statistic for heterogeneity =
10.59, DF = 3, p = 0.014, I2 = 71.7%, 95%CI 19.5–90%).
The pooled relative risk of death for any cause was 1.8
(95%CI 1.18–2.77; p = 0.007) (Q statistic for heterogene-
ity = 0.82, DF = 2, p = 0.66 I2 = 0), the corresponding
pooled risk difference was 0.01 (95%CI 0.001–0.012; p =
0.03), (Q statistic for heterogeneity = 3.09, DF = 3, p =
0.38, I2 = 2.9%, 95%CI 0–85.1%).
Conclusion
This meta-analysis suggests that in patients undergoing a
treatment interruption there is an increased relative risk of
developing AIDS or death; this risk is decreased if a rela-
tively high CD4+ threshold is chosen to reinitiate the
treatment. The pooled risk difference was of small entity
and did not reach statistical significance.
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